Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - Pharmaceutical News - Nemaura Pharma Memspatch Addresses Diabetics Fear of Needle Puncture Pain - November 18, 2017

Pharmacy News Article

 5/18/17 - Nemaura Pharma Memspatch Addresses Diabetics Fear of Needle Puncture Pain

LOUGHBOROUGH, England(BUSINESS WIRE) Results of recent clinical trials carried out on type 1 diabetics by Nemaura Pharma using its Memspatch Insulin Micro-needle Device (IMD) will come as a relief to those who fear needles and injections, a condition medically known as trypanophobia, affecting 10 percent of the world's population.

Nemaura's Memspatch IMD compared favourably against a commonly-use marketed Pen Injector (PI). The single-site clinical study involving 18 Type 1 diabetic patients took place over two periods, with a pain assessment performed on each visit to evaluate the severity of the pain. The Numeric Pain Rating Score system 0 10 was used; which scores no pain at 0, through to 10 indicating the most intense pain sensation imaginable. Patients were asked to record their experience of the respective IMD and PI devices and to think about the intensity, sharpness and itchiness of the pain immediately after administration.

Whilst pain intensity and sharpness inflicted by the PI reached 5 for several patients, the Memspatch IMD recorded 0 or 1 when applied to the arm or thigh.

These major reductions in pain levels are a result of the novel approach Nemaura has taken to drug delivery systems. The Memspatch IMD is held flat against the skin, with skin-penetration confined to a depth of 2mm to 4mm, which is less than half the usual 9mm depth for pen injector needles. Insulin delivery through shallow micro-needles requires little training or basic skills, making self-medication much easier.

Commenting on the study results, Nemaura CEO Dr Faz Chowdhury said: Needle phobia is a major barrier to health. We have looked carefully at the human factors restricting diabetics wanting to self-administer insulin, and have developed the Memspatch IMD to avoid puncture pain, and to improve treatment compliance. Over 50 percent of adults with Type 2 Diabetes delay starting insulin due to needle fear, and over 90 percent feel fear reactions every time they inject. So we would encourage the take-up of Memspatch IMD technology to help diabetics better manage their condition.

Further Memspatch tests are planned later this year on a broad range of other medicines alongside insulin, as Nemaura moves towards commercial partner agreements on multiple medical conditions.

In 2016, Nemaura received Frost & Sullivan recognition of its advanced micro-needle capability in skin drug delivery. Nemaura aims to be one of the leading pharmaceutical technologists in this fast growing market, which is expected to be worth 33billion by 2018.

Founded in 2005, Nemaura has patents secured or pending across multiple patent families and now employs over 25 medical device technologists and bio scientists based on the Loughborough University Science and Enterprise Park.

ENDS

(Aronson R, DIABETES TECH & THERAP 2012 14(8):741-7; Kruger DF Diabetes met 2015:8;49-56).

About Nemaura Pharma

www.nemaura.co.uk

Founded in 2005, Nemaura Pharma is a private specialist biotech company with headquarters and research facilities in the Advanced Technology Centre on the Loughborough University Science and Enterprise Park (LUSEP) in the United Kingdom.

The company employs multi-disciplinary teams of scientists and engineers working in cutting-edge innovative drug formulation and medical device technologies designed to radically improve the way drugs are administered through the skin. It has patents secured or pending in multiple countries across numerous patent families.

The company has secured over 25m (over $30m) in licensing and development payments, and private investment. In addition, Nemaura has been awarded five highly competitive British Government grants, and the Frost & Sullivan 2016 Enabling Technology Leadership Award in Transdermal Drug Delivery.

Cautionary Statement Regarding Forward-Looking Statements.

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements.

Nemaura Pharma

Media enquiries:

Louise Third

+44 (0) 7773 288342

pr@nemaura.co.uk

or

Business Development enquiries:

David Scott

+ 44 (0)1509 222 912

bd@nemaura.co.uk

Source: Nemaura Pharma



Copyright Business Wire 2017

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415